Dexloxiglumide is a drug which acts as a
cholecystokinin antagonist, selective for the
CCKA subtype. It inhibits gastrointestinal motility and reduces gastric secretions, and despite older selective CCKA antagonists such as
lorglumide and
devazepide having had only limited success in trials and ultimately never making it into clinical use, dexloxiglumide is being investigated as a potential treatment for a variety of gastrointestinal problems including
irritable bowel syndrome,[1]dyspepsia,[2]constipation[3] and
pancreatitis,[4][5] and has had moderate success so far although trials are still ongoing.
References
^Cremonini F, Camilleri M, McKinzie S, Carlson P, Camilleri CE, Burton D, et al. (March 2005). "Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study". The American Journal of Gastroenterology. 100 (3): 652–63.
doi:
10.1111/j.1572-0241.2005.41081.x.
PMID15743365.
S2CID34227592.
^Roberts DJ, Banh HL, Hall RI (August 2006). "Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients". Current Opinion in Critical Care. 12 (4): 295–302.
doi:
10.1097/01.ccx.0000235205.54579.5d.
PMID16810038.
S2CID32307333.
^Maselli MA, Mennuni L (September 2003). "CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications". Minerva Gastroenterologica e Dietologica. 49 (3): 211–6.
PMID16484960.